Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 9/20 | 0.56 |
| ▸ | EGFR | P00533 | 8/20 | 0.56 |
| ▸ | ABL2 | P42684 | 8/20 | 0.56 |
| ▸ | SRC | P12931 | 12/20 | 0.53 |
| ▸ | LCK | P06239 | 4/20 | 0.51 |
| ▸ | KDR | P35968 | 3/20 | 0.51 |
| ▸ | TEK | Q02763 | 1/20 | 0.51 |
| ▸ | FLT3 | P36888 | 4/20 | 0.50 |
| ▸ | RET | P07949 | 3/20 | 0.50 |
| ▸ | IGF1R | P08069 | 3/20 | 0.50 |
| ▸ | KIF5B | P33176 | 3/20 | 0.50 |
| ▸ | JAK2 | O60674 | 2/20 | 0.50 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.50 |
| ▸ | INSR | P06213 | 2/20 | 0.50 |
| ▸ | NPM1 | P06748 | 2/20 | 0.50 |
| ▸ | CSF1R | P07333 | 2/20 | 0.50 |
| ▸ | LYN | P07948 | 2/20 | 0.50 |
| ▸ | MET | P08581 | 2/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.50 |
| ▸ | KIT | P10721 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL398056 | 1.00 | ABL1 (0.56) | ABL1EGFRABL2SRCLCK | |
| SCHEMBL13111440 | 1.00 | ABL1 (0.56) | ABL1EGFRABL2SRCLCK | |
| SCHEMBL399666 | 1.00 | ABL1 (0.56) | ABL1EGFRABL2SRCLCK | |
| SCHEMBL399498 | 0.92 | SRC (0.59) | ABL1EGFRABL2SRCLCK | |
| SCHEMBL11911378 | 0.92 | ABL1 (0.56) | ABL1EGFRABL2SRCLCK | |
| SCHEMBL401691 | 0.89 | ABL1 (0.72) | ABL1EGFRABL2SRCLCK | |
| SCHEMBL13597767 | 0.88 | SRC (0.54) | ABL1EGFRABL2SRCLCK | |
| Carbamic Acid SCHEMBL19244734 | 0.88 | EGFR (0.64) | ABL1EGFRABL2SRCLCK | |
| SCHEMBL396798 | 0.87 | SRC (0.68) | ABL1EGFRABL2SRCLCK | |
| SCHEMBL396799 | 0.87 | SRC (0.68) | ABL1EGFRABL2SRCLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2168968-B1 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS LLC (US) | 2017-08-23 | — | — | EP | disclosed |
| EP-2168968-B1 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS LLC (US) | 2017-08-23 | — | — | EP | disclosed |
| US-8735405-B2 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735405-B2 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735405-B2 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2014-05-27 | — | — | US | disclosed |
| US-8653268-B2 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2014-02-18 | — | — | US | disclosed |
| US-8653268-B2 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2014-02-18 | — | — | US | disclosed |
| US-8575164-B2 | Combination cancer therapy | OSI Pharmaceuticals, LLC (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575164-B2 | Combination cancer therapy | OSI Pharmaceuticals, LLC (US) | 2013-11-05 | — | — | US | disclosed |
| US-20130190496-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI Pharmaceuticals, LLC | 2013-07-25 | — | — | US | disclosed |
| US-20090118499-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
| US-20080299113-A1 | Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents | OSI PHARMACEUTICALS, INC. | 2008-12-04 | — | — | US | disclosed |
| US-20080299113-A1 | Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents | OSI PHARMACEUTICALS, INC. | 2008-12-04 | — | — | US | disclosed |
| US-20080267957-A1 | Combination cancer therapy | OSI PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080267957-A1 | Combination cancer therapy | OSI PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | disclosed |
| WO-2008076143-A1 | COMBINATION OF IGFR INHIBITOR AND ANTI-CANCER AGENT | OSI PHARMACEUTICALS, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| US-20080014200-A1 | Combined treatment with 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents | OSI PHARMACEUTICALS, INC. | 2008-01-17 | — | — | US | disclosed |
| US-20080014200-A1 | Combined treatment with 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents | OSI PHARMACEUTICALS, INC. | 2008-01-17 | — | — | US | disclosed |
| WO-2007075554-A2 | COMBINATION OF IGFR INHIBITOR AND ANTI-CANCER AGENT | OSI PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20060235031-A1 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | ACERTA PHARMA B.V. (NL) | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190496-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | IGF1R, MAP2K7, BRCA1 | ABL1 621/4885EGFR 155/4885ABL2 1513/4885 |
| US-20080014200-A1 | Combined treatment with 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents | IGF1R, IGFBP6, CDK6 | ABL1 191/4885EGFR 27/4885ABL2 1406/4885 |
| US-20090118499-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | IGF1R, MAP2K7, BRCA1 | ABL1 621/4885EGFR 155/4885ABL2 1513/4885 |
| US-20080299113-A1 | Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents | IGF1R, EGFR, ERBB2 | ABL1 36/4885EGFR 2/4885ABL2 529/4885 |
| US-20080267957-A1 | Combination cancer therapy | IGF1R, IGFBP4, IGFBP1 | ABL1 179/4885EGFR 11/4885ABL2 1291/4885 |
| US-20060235031-A1 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | IGF1R, MAP2K7, BRCA1 | ABL1 621/4885EGFR 155/4885ABL2 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.